October 2008: The US National Cancer Institute has notified PDS Biotechnology of a contract award to perform pre-IND animal toxicology studies for Versamune™ –HPV, an immunotherapy being developed to treat cervical cancer and other HPV-related cancers and infections.

September 2008: The US National Cancer Institute has awarded PDS Biotechnology its second SBIR grant to develop Versamune™ –Melanoma, an immunotherapy for melanoma. The first grant focused on Versamune™ –HPV currently in pre-clinical development.

September 2008: Dr. Mark Einstein, M.S., M.D., Director of Clinical Research, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, and Montefiore Medical Center, an internationally renowned cervical cancer researcher and clinical expert in HPV-related disease joins PDS Biotechnology's scientific advisory board.

Welcome to PDS Biotechnology Corporation

Simple, safe and innovative immunotherapies targeting infectious diseases and cancer

PDS Biotechnology Corporation is a biopharmaceutical company pioneering the development of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.

Unlike typical cancer and antiviral immunotherapies, our patented nanoparticle technology both facilitates the uptake of disease-associated proteins and peptides by the cells of the immune system and simultaneously activates the immune system to generate a strong and specific immune response against the infected cells in the body, resulting in eradication of the cancer or viral disease. Superior tumor regression has been demonstrated in preclinical studies of our lead cervical cancer product Versamune™ -HPV in head-to-head comparisons with leading technologies.

The company's mission is to utilize its proprietary technology to develop immunotherapies to treat specific cancers and infectious diseases for which no cures exist.